Tara Arvedson
Chief Scientific Officer Hexagon Bio
Seminars
Friday 6th November 2026
Reprogramming ADC Resistance Through Mechanistically Matched Payload Combinations
11:15 am
- Analyze ADC resistance mechanisms in topoisomerase and tubulin payloads, including drug efflux pumps and tumor bypass pathways, and distinguish where evidence remains strong versus where it is still incomplete
- Explore approaches to overcoming resistance through rational payload selection, including combining topoisomerase inhibitors with PARP or ATR inhibitors and using translation inhibition strategies to prevent efflux pump expression and resensitize tumors
- Define key requirements for effective dual payload ADC design, including matched payload potency, coordinated intracellular release timing, and engineering strategies that ensure both payloads reach and act in tumor cells simultaneously
Wednesday 4th November 2026
Engineering Dual Payload ADCs to Expand Therapeutic Window, Overcome Resistance & Unlock Novel Synergies
9:00 am
This workshop examines the emerging complexity of dual- and multi-payload ADC design, where the promise of enhanced efficacy through mechanistic synergy must be balanced against fundamental constraints in biology, chemistry, and translational predictability. It asks whether combining payloads truly expands the therapeutic window or whether it introduces new layers of variability in exposure, toxicity, and resistance evolution.
- Explore how dual and multi payload ADCs are enabling synergistic mechanisms that outperform traditional combination approaches
- Understand how rational payload pairing strategies can expand addressable patient populations and overcome emerging resistance mechanisms
- Examine the chemistry and translational challenges associated with linker payload synthesis, in vivo evaluation, and optimization of dual payload systems
- Learn how developers are integrating novel payload classes alongside established cytotoxics to revive promising mechanisms and differentiate next generation ADCs
- Assess evolving clinical and preclinical data supporting dual payload approaches and identify where the field is seeing meaningful therapeutic advantage
